Quarterly Results

202603 Results Summary

Revenue

The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Operating Profit

Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

PBDT

PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Profit Before Tax

Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Net Profit

Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Company News

More

Earnings

CategoryQ3 FY25-26Q3 FY24-25Change %FY24-25FY23-24Change %
Total Revenue7,167.525,767.7124.2722,707.9020,010.8213.48
Expenses5,332.244,411.8120.8617,424.5916,200.307.56
Other Income114.7053.71113.55195.82120.1762.95
Operating Profit1,835.281,355.9035.365,479.133,930.6939.39
Depreciation312.96271.4515.291,169.261,196.81-2.30
Interest114.9866.8971.89294.87311.61-5.37
Profit Before Tax1,522.041,071.2742.084,015.002,422.2765.75
Tax341.53212.4160.79990.69633.8556.30
Net Profit1,180.51858.8637.453,306.261,935.5770.82
CategoryQ3 FY25-26Q2 FY25-26Change %
Total Revenue7,167.527,047.511.70
Expenses5,332.244,706.1813.30
Other Income114.7090.0027.44
Operating Profit1,835.282,341.33-21.61
Depreciation312.96316.77-1.20
Interest114.98107.596.87
Profit Before Tax1,522.042,006.97-24.16
Tax341.53522.14-34.59
Net Profit1,180.511,484.83-20.50

Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Financial Reports

Data not available.

Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Data Not Found

Corporate Information

Company News

Stocks to buy today: Analyst at Kotak Sec bets on ICICI Bank, Lupin

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

Updated On: 17 Feb 2026 | 7:27 AM IST

Lupin rises post-Q3 analysts call, but brokerages flag FY27 earnings risk

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

Updated On: 16 Feb 2026 | 9:51 AM IST

Stocks to Watch today: Bharti Airtel, LIC, Trent, NSDL, Tata Power, Marico

Stocks to Watch today, February 5, 2026: Medanta, JSW Cement, Cummins India, Emcure Pharma, Bajaj Finserv, Metropolis, Emami, Lupin, and NHPC are among the top stocks to watch today

Updated On: 05 Feb 2026 | 7:01 AM IST

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Updated On: 03 Feb 2026 | 9:49 AM IST

Nifty seen in tight range; BSE, Lupin among Ajit Mishra's stock picks

Nifty prediction today: Continued profit booking and earnings-related reactions in select heavyweights may limit the pace of any immediate recovery in Nifty, said Ajit Mishra of Religare Broking.

Updated On: 08 Jan 2026 | 7:41 AM IST

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Updated On: 07 Jan 2026 | 12:14 PM IST

Lupin signs exclusive India pact with Gan & Lee for fortnightly GLP-1 drug

Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India

Updated On: 29 Dec 2025 | 8:56 PM IST

US portfolio, margin expansion to drive gains for pharma major Lupin

Complex generics and better mix fuel recovery cycle

Updated On: 02 Dec 2025 | 2:33 PM IST

Stocks to Watch today, Nov 17: Maruti Suzuki, Ola Electric, Marico, Lupin

Stocks to Watch Today, November 17, 2025: Marico, Glenmark Pharma, FirstCry, Siemens, Dish TV, Alembic Pharma, Cyient, and Websol Energy System are among the top stocks to remain in focus today

Updated On: 17 Nov 2025 | 7:17 AM IST

Trading guide: Nifty eyes 26,000; CDSL, Lupin, Nestle on analyst radar

Ajit Mishra, SVP-Research at Religare Broking, has recommended buying CDSL, Nestle India, and Lupin stocks today. Check key rationales here

Updated On: 13 Nov 2025 | 7:02 AM IST
More